Navigation Links
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
Date:7/7/2009

r others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the c
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
2. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
3. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
4. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
5. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
6. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
7. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
10. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
11. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013   Accuray Incorporated ... publication of study results involving hundreds of prostate ... System, the most widely used form of prostate ... 304 patients for a median of 5 years, ... that 97 percent of patients with low-risk and ...
(Date:5/21/2013)... ORLANDO, Fla. , May 21, 2013 /PRNewswire/ ... and safety results from the global Phase 3 ... protease inhibitor simeprevir (TMC435) led to sustained virologic ... (SVR12) in 79 percent of treatment-experienced genotype 1 ... disease, including all stages of liver fibrosis, when ...
(Date:5/21/2013)... 21, 2013 Abaxis, Inc. (NasdaqGS: ABAX), a ... today that Martin Mulroy , chief ... Dental & Veterinary Conference on Wednesday, May 29, 2013 ... at Le Parker Meridien Hotel in New ... Abaxis develops, manufactures, markets and sells portable blood ...
Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2
(Date:5/21/2013)... HealthDay Reporter , , MONDAY, May 20 (HealthDay News) ... drowsy run a higher risk of getting into car ... up on missed sleep on weekends puts them in ... "This is another challenge to adolescents that comes ... director and founder of the Center for Injury Research ...
(Date:5/21/2013)... of non-small cell lung cancer (NSCLC) in U.S. hospitals ... according to a new study., "In most patients, the ... is surgery," said researcher Jayanth Adusumalli, MBBS, of the ... study of more than 1,200,000 patients diagnosed with NSCLC ... we found statistically significant racial disparities in the surgical ...
(Date:5/21/2013)... an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring ... protects the lung,s elasticity, is effective in slowing ... antitrypsin deficiency (AATD), a life-threatening genetic disorder, according ... American Thoracic Society International Conference. , The study ... of lung tissue as measured by computed tomography ...
(Date:5/21/2013)... 2013 According to the Los ... to make possession of controlled substances (heroin, cocaine, crystal ... offense. MacGregor & Collins Orange County criminal lawyers believe ... overcrowding as well as improving rehabilitation rates amongst controlled ... bill met a great deal of resistance from the ...
(Date:5/21/2013)... 21, 2013 The first ever over-the-counter ... Seal, Anti Itchbalm, is ready to come to pharmacies ... and effective product which will help attract more customers ... community. , US Organic Group Corp. has developed Anti ... can be safely used on both adults and children, ...
Breaking Medicine News(10 mins):Health News:Weekend 'Catch-Up' Sleep May Cut Young Drivers' Crash Risk 2Health News:Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency 2Health News:Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency 3Health News:New Drug Bill to Lower Penalties for Possession of Controlled Substances Gains Support from Criminal Lawyers 2Health News:First Ever Over-the-Counter Organic Anti-Itch Ointment Developed by US Organic Group Corp. 2
... that craving a cigarette while performing a cognitive task ... wandering, but also makes that person less likely to ... The paper, titled "Out for a Smoke: The Impact ... the first evidence that craving disrupts an individual,s meta-awareness, ...
... , INDIANAPOLIS, Dec. 7 ... the availability of a smaller insulin vial, the first in the ... with diabetes being treated in a hospital. , The new smaller ... origin]) and Humulin® R-U100 (regular insulin human injection, ...
... , HORSHAM, Pa., Dec. 7 ... TEVA ), today announced the publication of four articles ... Journal of Allergy and Clinical Immunology (JACI), providing ... small airways in the understanding and treatment of asthma. This ...
... new University of Pittsburgh study reveals that craving a ... the chances of a person,s mind wandering, but also ... or her mind has wandered. The paper, titled ... on Zoning Out During Reading," provides the first evidence ...
... ... Hunt, a range of experts and healthcare leaders will focus on sharing best practices ... industries will discuss lessons learned in developing functional health information exchanges which provide safer ... ...
... who have been infected with West Nile virus may ... initial infection, potentially leading to kidney problems. The research, ... Journal of Infectious Diseases , is now available ... West Nile virus was first detected in the United ...
Cached Medicine News:Health News:Pitt study suggests craving hinders comprehension without your realizing it 2Health News:Lilly Announces the First 300-unit Vial of Insulin 2Health News:Lilly Announces the First 300-unit Vial of Insulin 3Health News:Lilly Announces the First 300-unit Vial of Insulin 4Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 2Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 3Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 4Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 5Health News:Pitt study suggests craving hinders comprehension without you realizing it 2Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 2Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 3Health News:West Nile virus infection may persist in kidneys years after initial infection 2Health News:West Nile virus infection may persist in kidneys years after initial infection 3
... is a state-of-the-art hair reduction and ... specially designed for use within a ... features and economy in a single ... treatment of unwanted hair, photo rejuvenation ...
... perfect mix of powerful, versatile, and innovative ... Palomar StarLux® Pulsed Light and Laser System.,With ... compact base unit so theres no ... treatments., You can choose among Laser, Intense ...
Perfect for physicians who prefer a Heavier and Longer tubing, permitting them maximum access around the OR table. 12 feet in length Sizes availabe to fit any vacuum canisters...
... Pump provides optimum flow rate ... Operates on any voltage worldwide. ... safety Interlock and easy load ... Double Spike Tubing, Dual Pneumatic ...
Medicine Products: